Chronic Lymphocytic Leukemia News and Research

RSS
Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.
CytRx commences INNO-206 Phase 2 clinical trial for pancreatic cancer

CytRx commences INNO-206 Phase 2 clinical trial for pancreatic cancer

Expression of specific GPCRs appears to play a role in prognosis of CLL

Expression of specific GPCRs appears to play a role in prognosis of CLL

ImmunoGen commences IMGN529 Phase I trial in NHL

ImmunoGen commences IMGN529 Phase I trial in NHL

NASDAQ notifies CytRx of non-compliance with minimum bid price requirement

NASDAQ notifies CytRx of non-compliance with minimum bid price requirement

Celgene signs definitive merger agreement to acquire Avila

Celgene signs definitive merger agreement to acquire Avila

TrovaGene acquires license to mutations of SF3B1 splicing factor in CLL

TrovaGene acquires license to mutations of SF3B1 splicing factor in CLL

Emergent commences Phase 2 combination trial of TRUw-016 with bendamustine in relapsed CLL

Emergent commences Phase 2 combination trial of TRUw-016 with bendamustine in relapsed CLL

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

DNA sequencing identifies new altered genes that drive CLL

DNA sequencing identifies new altered genes that drive CLL

KPT-SINE shows promise against CLL

KPT-SINE shows promise against CLL

Treatment with leukemia patients' own cells may prevent infections after chemotherapy

Treatment with leukemia patients' own cells may prevent infections after chemotherapy

Celgene announces interim results of REVLIMID study on CLL

Celgene announces interim results of REVLIMID study on CLL

PCI-32765 is highly active and well tolerated in patients with CLL

PCI-32765 is highly active and well tolerated in patients with CLL

New findings from Micromet's blinatumomab phase 1 trial on DLBCL

New findings from Micromet's blinatumomab phase 1 trial on DLBCL

New research on diagnosis and treatment of leukemia to be presented at 53rd ASH meeting

New research on diagnosis and treatment of leukemia to be presented at 53rd ASH meeting

SCRI to present findings of blood cancer trials at 53rd ASH annual meeting

SCRI to present findings of blood cancer trials at 53rd ASH annual meeting

PCI-32765 produces durable remissions in Phase I/II CLL clinical trial

PCI-32765 produces durable remissions in Phase I/II CLL clinical trial

Memgen to present ISF35 clinical trial data on CLL at 53rd ASH meeting

Memgen to present ISF35 clinical trial data on CLL at 53rd ASH meeting

Pharmacyclics, Janssen partner to develop and market PCI-32765 anti-cancer compound

Pharmacyclics, Janssen partner to develop and market PCI-32765 anti-cancer compound

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.